Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

VK2735

Stage Phase 3Stale

Sponsor Viking Therapeutics, Inc.

Route subcutaneous

Class GLP-1/GIP

Mechanism glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor dual agonist

Target GLP-1/GIP receptor (TEC-0013)

Sources

registry, as of 2025-11-24Stale

https://clinicaltrials.gov/study/NCT07104500

Protocol section, NCT07104500 VANQUISH 1, last update posted 2025-11-24

registry, as of 2025-02-12Stale

https://clinicaltrials.gov/study/NCT06068946

Protocol section, NCT06068946 VENTURE, last update posted 2025-02-12

publication, as of 2026-01-08Stale

https://pubmed.ncbi.nlm.nih.gov/41508550/

VENTURE was a phase 2, randomized, double-blind, placebo-controlled, dose-ranging study of weekly subcutaneous VK2735, a novel glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor dual agonist. Mean weight reduction with active treatment ranged from 9.2 kg (2.5 mg dose) to 14.6 kg (15 mg dose), corresponding to 9.1% and 14.7% weight reductions, respectively; the placebo group had a 1.8 kg (1.7%) reduction.

Obesity (Silver Spring) 2026;34:537-549, PMID 41508550, abstract

registry, as of 2026-04-07Stale

https://clinicaltrials.gov/study/NCT07104383

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Viking Therapeutics, Inc.. Enrollment 1100. Conditions Weight Loss. This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obe

ClinicalTrials.gov NCT07104383 protocol and results modules

Studies

VENTURE

Registry NCT06068946

Phase Phase 2

Status Completed

Enrollment 176

Start 2023-08-31

Primary completion 2024-02-27

Study completion 2024-04-02

VK2735 (Placebo)

VK2735 (Dose #1)

VK2735 (Dose #2)

VK2735 (Dose #3)

VK2735 (Dose #4)

VK2735 2.5 mg

Dose 2.5 mg

Regimen once weekly

Weeks 13

Comparator placebo

Population Adults with obesity or overweight and at least 1 weight-related comorbidity. Participants with diabetes mellitus were ineligible.

percent change from baseline in body weight, -9.1 %, week 13

change in body weight, -9.2 kg, week 13

VK2735 15 mg

Dose 15 mg

Regimen once weekly

Weeks 13

Comparator placebo

Population Adults with obesity or overweight and at least 1 weight-related comorbidity. Participants with diabetes mellitus were ineligible.

percent change from baseline in body weight, -14.7 %, week 13

change in body weight, -14.6 kg, week 13

Placebo 13 weeks

Regimen once weekly

Weeks 13

Population Adults with obesity or overweight and at least 1 weight-related comorbidity. Participants with diabetes mellitus were ineligible.

percent change from baseline in body weight, -1.7 %, week 13

change in body weight, -1.8 kg, week 13

VANQUISH 1

Registry NCT07104500

Phase Phase 3

Status Active, not recruiting

Enrollment 4500

Start 2025-06-23

Primary completion 2027-07-01

Catalyst Primary completion. 2027-07-01Stale

Placebo Assignment

Active Assignment (Dose 1)

Active Assignment (Dose 2)

Active Assignment (Dose 3)

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Registry NCT07104383

Phase Phase 3

Status Active, not recruiting

Enrollment 1100

Start 2025-06-23

Primary completion 2027-07-01

Study completion 2027-08-01

Catalyst Primary completion. 2027-07-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Placebo Assignment

Regimen once weekly

Population Weight Loss

Active Assignment (Dose #1)

Regimen once weekly

Comparator placebo

Population Weight Loss

Active Assignment (Dose #2)

Regimen once weekly

Comparator placebo

Population Weight Loss

Active Assignment (Dose #3)

Regimen once weekly

Comparator placebo

Population Weight Loss